Pharmacological interventions that increase myofiber size counter the functional decline of dystrophic muscles. We show that deacetylase inhibitors increase the size of myofibers in dystrophin-deficient (MDX) and α-sarcoglycan (α-SG)-deficient mice by inducing the expression of the myostatin antagonist follistatin in satellite cells. Deacetylase inhibitor treatment conferred on dystrophic muscles resistance to contraction-coupled degeneration and alleviated both morphological and functional consequences of the primary genetic defect. These results provide a rationale for using deacetylase inhibitors in the pharmacological therapy of muscular dystrophies.
|Titolo:||Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors|
|Autori interni:||ADAMI, RAFFAELLA|
|Data di pubblicazione:||17-set-2006|
|Digital Object Identifier (DOI):||10.1038/nm1479|
|Appare nelle tipologie:||01 - Articolo su periodico|